January 17, 2025 07:02 AM EST
R&D

As­traZeneca wins BTK race to mar­ket in first-line man­tle cell lym­phoma

Elizabeth Cairns

Senior biopharma journalist

As­traZeneca’s Calquence be­came the first BTK in­hibitor ap­proved in the US for first-line use in man­tle cell lym­phoma on Thurs­day. The drug

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

A service from the Financial Times